Which statement correctly describes antihypertensive management in pregnancy?

Which statement correctly describes antihypertensive management in pregnancy?

• A. ACE inhibitors are the preferred agents in pregnancy.
• B. ARBs are recommended during pregnancy.
• C. Diuretics are the first-line therapy in pregnancy.
• D. Preferred in pregnancy: methyldopa, labetalol, and hydralazine; ACE inhibitors and ARBs contraindicated; diuretics used cautiously.

Answer: (D)

The important idea is that antihypertensive therapy in pregnancy must protect both the mother and the fetus, so drugs with proven fetal safety are chosen and drugs that can harm fetal development are avoided. The best description is that the preferred agents are methyldopa, labetalol, and hydralazine. Methyldopa has a long track record of safety in pregnancy because it lowers blood pressure by reducing central sympathetic outflow without significant adverse fetal effects. Labetalol provides effective BP control with a favorable safety profile thanks to its combined alpha- and beta-blocking actions, and hydralazine acts as a direct vasodilator that can be used when rapid BP management is needed, such as in hypertensive emergencies or severe hypertension, often given IV for quick effect. ACE inhibitors and ARBs are contraindicated in pregnancy because of clear fetal risks, including renal damage, oligohydramnios, growth restriction, and other congenital abnormalities, particularly with exposure during the second and third trimesters. That is why they are avoided entirely in pregnancy. Diuretics are not first-line for routine blood pressure control in pregnancy because they can reduce placental perfusion and macerate intravascular volume, though they may be used cautiously in specific situations (for example, certain edema or underlying heart/kidney disease). The key is to balance keeping the mother’s BP under control while minimizing any potential harm to the developing fetus, which is why the combination of methyldopa, labetalol, and hydralazine is emphasized as the preferred approach and ACE inhibitors/ARBs are avoided.

The important idea is that antihypertensive therapy in pregnancy must protect both the mother and the fetus, so drugs with proven fetal safety are chosen and drugs that can harm fetal development are avoided. The best description is that the preferred agents are methyldopa, labetalol, and hydralazine. Methyldopa has a long track record of safety in pregnancy because it lowers blood pressure by reducing central sympathetic outflow without significant adverse fetal effects. Labetalol provides effective BP control with a favorable safety profile thanks to its combined alpha- and beta-blocking actions, and hydralazine acts as a direct vasodilator that can be used when rapid BP management is needed, such as in hypertensive emergencies or severe hypertension, often given IV for quick effect.

ACE inhibitors and ARBs are contraindicated in pregnancy because of clear fetal risks, including renal damage, oligohydramnios, growth restriction, and other congenital abnormalities, particularly with exposure during the second and third trimesters. That is why they are avoided entirely in pregnancy.

Diuretics are not first-line for routine blood pressure control in pregnancy because they can reduce placental perfusion and macerate intravascular volume, though they may be used cautiously in specific situations (for example, certain edema or underlying heart/kidney disease). The key is to balance keeping the mother’s BP under control while minimizing any potential harm to the developing fetus, which is why the combination of methyldopa, labetalol, and hydralazine is emphasized as the preferred approach and ACE inhibitors/ARBs are avoided.